Engagement between immuneand tumor cells could be controlled by distinctly engineered molecules,including chimeric antigen T-cell receptors (CAR Ts) and bispecificT-cell engagers (BiTEs),21−23 which are designed to selectivelyrecruit T-cells to the tumor site. This evidence concerns the gene TARP and neoplasm.